Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.
about
A gammaherpesvirus Bcl-2 ortholog blocks B cell receptor-mediated apoptosis and promotes the survival of developing B cells in vivoRapamycin induces pluripotent genes associated with avoidance of replicative senescenceTargeting of Chk2 as a countermeasure to dose-limiting toxicity triggered by topoisomerase-II (TOP2) poisonsDissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activityChronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonismHomozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death.Loss of nucleolar histone chaperone NPM1 triggers rearrangement of heterochromatin and synergizes with a deficiency in DNA methyltransferase DNMT3A to drive ribosomal DNA transcription.Promoter occupancy of STAT1 in interferon responses is regulated by processive transcription.Awakening guardian angels: drugging the p53 pathway.p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome.Wild type p53 reactivation: from lab bench to clinic.High levels of TopBP1 induce ATR-dependent shut-down of rRNA transcription and nucleolar segregation.Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity.Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell cultureRibosomal Protein Mutations Result in Constitutive p53 Protein Degradation through Impairment of the AKT PathwayImportin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesisTreatment-induced cell cycle kinetics dictate tumor response to chemotherapyRecent progress in targeting cancer.NCI's provocative questions on cancer: some answers to ignite discussion.Towards an understanding of the role of p53 in adrenocortical carcinogenesis.An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells.Wt p53 impairs response to chemotherapy: make lemonade to spare normal cellsp53 is a major component of the transcriptional and apoptotic program regulated by PI 3-kinase/Akt/GSK3 signalingRecent discoveries in the cycling, growing and aging of the p53 fieldRecent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapyp53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy.Human p53 interacts with the elongating RNAPII complex and is required for the release of actinomycin D induced transcription blockage.Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.AKT mediates actinomycin D-induced p53 expression.p53-based cancer therapyInhibiting eukaryotic transcription: Which compound to choose? How to evaluate its activity?Nucleolar control of p53: a cellular Achilles' heel and a target for cancer therapy.p53 and ribosome biogenesis stress: the essentials.Regulation of ribosomal gene expression in cancer.Pharmacological reactivation of p53 as a strategy to treat cancer.Transcriptional repressor NIR interacts with the p53-inhibiting ubiquitin ligase MDM2.An in vitro study of the interaction of the chemotherapeutic drug Actinomycin D with lung cancer cell lines using Raman micro-spectroscopy.p53 induction and cell viability modulation by genotoxic individual chemicals and mixtures.
P2860
Q28539635-BA3FC4D4-A002-4349-882D-944615F97443Q28572137-EB0520C4-50D8-445A-B4C5-B0A64634FDDAQ28828183-7EC9F318-4DBF-40E7-BD2B-5B78E7CD8132Q33576843-D37A04D3-8F98-4692-9449-91E846C8803CQ34079481-085B9AC0-C03B-4AC3-BCB7-9FD47CA6C537Q34496093-5EC3E1BD-2FB9-4F14-88CB-33225BB64676Q34683193-D3931AEA-4DF1-4EC3-8F3D-E8B79990BBCAQ34994637-1AAC4DFD-E7DF-4549-9A3A-EEEB21C2DDA0Q35014385-5EF5B2CC-C9B7-4EA6-9069-DCCAA3EA07E1Q35103179-E00BBB99-E614-4DEE-8222-27EE3C13289FQ35146343-ABE32670-C873-4C8F-93E3-7471C083BEADQ35656774-1192E37E-6E4F-4694-AADD-9AD4ACAF7383Q35679369-B60A20FA-D2C4-4C81-903A-4FD39AEFC56FQ35679387-97E3B0DD-125D-4FEA-B4FC-27482212DD1CQ35680232-19F8BB6A-E941-47C0-B617-3A80BBC98970Q35724796-6CFDEE5C-9F70-477F-8750-DF19CFA838F2Q35740145-76718A6C-C0C8-4E6A-8FE8-3EF94D1BF4E9Q35740782-714E1E58-AC24-4FDE-8696-A9B258615926Q35764401-3B9C0088-B50E-4E8F-B0CE-40DC19CC5741Q35783751-CE49BDD0-59C5-4EBE-905A-43DDE389B2BDQ36023740-8A5F949C-5DAC-4086-A76C-AABE816AEA97Q36234051-8D63B8C1-A012-4683-888B-C39CAE4B97C5Q36347218-4849ABED-5D63-4F2D-B5E6-53D8B9E27F0FQ36736358-0DA5CCC6-8EC1-4DE6-A094-DC4E62E09CE2Q36926098-063A157D-C7BC-4C78-8BD7-AEDE2A9A53C4Q37192611-3C9DDE92-12DC-477D-891B-2A40E22CC37CQ37192616-437FA96D-7558-4FED-946F-A5A429B57F67Q37385293-1D738D87-B074-472D-A3CD-454D93F1F075Q37593366-AF0973DE-A21B-4C8A-AF8A-F7B2A258120FQ37641698-D4160888-B885-4991-8E8C-3125830479F4Q37718441-830EF32F-6858-4739-9E12-6117A3DBFFD0Q37750115-64BB683D-A866-4611-B6B7-72DC497F5AB2Q37933073-05D03E01-7ED8-4EF1-BA4C-BA203A8CD16FQ38107795-450DF49D-97A2-41F0-B3A3-730DF8022B11Q38205676-2AF8CE02-C89B-4BDE-9562-1B276FE185DCQ38261874-73CE4DD1-9F6B-4B3C-8DAA-56B948D1C7FCQ38286198-A9B96D6E-C6E3-47D2-A84C-3E04ACBE0D2AQ38594197-6A6FBD2B-9A63-4DE0-917C-AC44EF589A40Q38681280-89FE28E5-A77E-4F9A-9D38-90471DF70CFBQ38711897-C1C1D2CD-CBAD-4AEB-AB84-BA6A54014E5B
P2860
Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Specific activation of the p53 ...... ute to p53 based cyclotherapy.
@en
Specific activation of the p53 ...... ute to p53 based cyclotherapy.
@nl
type
label
Specific activation of the p53 ...... ute to p53 based cyclotherapy.
@en
Specific activation of the p53 ...... ute to p53 based cyclotherapy.
@nl
prefLabel
Specific activation of the p53 ...... ute to p53 based cyclotherapy.
@en
Specific activation of the p53 ...... ute to p53 based cyclotherapy.
@nl
P356
P1433
P1476
Specific activation of the p53 ...... oute to p53 based cyclotherapy
@en
P2093
Henry Yang
May Ann Lee
P304
P356
10.4161/CC.8.17.9503
P577
2009-09-13T00:00:00Z